Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Global Prevalence of Cardiac Disorders such as Strokes and Coronary Heart Failures
4.2.2 Growing R&D Investments in Gene and Peptide Therapy for Efficient Drugs and Reimbursement Policies
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework and Highly Expensive Patented Drugs
4.3.2 Adoption of Advanced Medical Devices like Pacemakers, Defibrillators instead of Cardiovascular Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Drug Class
5.1.1 Anti-hyperlipidemics
5.1.2 Anti-hypertensives
5.1.3 Anti-coagulants
5.1.4 Anti-arrhythmics
5.1.5 Others
5.2 Disease Indications
5.2.1 Hypertension
5.2.2 Hyperlipidemia
5.2.3 Coronary Artery Disease
5.2.4 Arrhythmia
5.2.5 Others
5.3 Distribution Channel
5.3.1 Hospitals
5.3.2 Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United states
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc
6.1.2 Baxter International Inc
6.1.3 C. H. Boehringer Sohn AG & Co KG
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Gilead Sciences Inc
6.1.6 Johnson & Johnson
6.1.7 Merck & Co Inc
6.1.8 Novartis International AG
6.1.9 Pfizer Inc
6.1.10 Sanofi S A


7 MARKET OPPORTUNITIES AND FUTURE TRENDS